MARKET

BFRA

BFRA

Biofrontera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.57
+0.07
+0.93%
Closed 16:00 10/20 EDT
OPEN
7.62
PREV CLOSE
7.50
HIGH
7.66
LOW
7.26
VOLUME
90.00K
TURNOVER
--
52 WEEK HIGH
55.00
52 WEEK LOW
5.26
MARKET CAP
169.75M
P/E (TTM)
-6.2572
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Biofrontera AG: Receives reasons from the Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court
Leverkusen, Germany, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, had announced on September 22, 2020, that in a ruling from September 22, 2020, the German Federal Supreme Court has overturned a decision by the Cologne Higher Regional Court dated November 15, 2018, which was directed against the Company. The case was referred back to the Cologne Higher Regional Court for retrial and decision. Biofrontera AG has now received the statement of reasons of the German Federal Supreme Court regarding the reversal of the ruling by the Cologne Higher Regional Court. The Cologne Higher Regional Court, following an action for annulment and rescission by a shareholder, Deutsche Balaton AG, had annulled the resolution of the Annual General Meeting held on May 24, 2017, which granted discharge to the Management Board of Biofrontera AG for fiscal year 2016. In its reasons for the decision, the Cologne Higher Regional Court assumed that the Management Board had violated the requirement of equal treatment of shareholders in connection with a capital increase carried out in October/November 2016 in a severe and unequivocal manner. The German Federal Supreme Court has now determined that the violation of law assumed by the Cologne Higher Regional Court has not occurred.While the ruling of the Cologne Higher Regional Court had not become legally binding, the reasoning for the ruling - the alleged significant violation of the duties of the Management Board -was repeatedly publicly communicated or quoted by interested parties (e.g. in countermotions to annual general meetings or at annual general meetings themselves). According to the ruling of the German Federal Supreme Court, however, the nullification of the discharge resolution could not be based on the grounds given by the Cologne Higher Regional Court.Furthermore, the Annual General Meeting held on May 24, 2017, had resolved to create new authorized capital. The Cologne Higher Regional Court had also declared this resolution null and void, since the Annual General Shareholders' Meeting had allegedly acted in bad faith towards the plaintiff when passing the resolution. This reasoning also failed to pass the review by the German Federal Supreme Court. -End-For enquiries, please contact: Biofrontera AG Thomas Schaffer, Chief Financial Officer  +49 (0) 214 87 63 2 0 ir@biofrontera.com IR UK: Seton Services Toni Vallen  +44 (0) 207 229 0805 About Biofrontera:Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi™ for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.
GlobeNewswire · 10/14 08:30
Biofrontera provides preliminary revenue figures
The Biofrontera-Group ([[BFRA]]) Q3 preliminary revenue €4.7M-4.9M, about 9% less than in Q3 2019.Company generated total preliminary unaudited revenue of ~€20.8M-21.0M in the period from January 1st to September 30th, 2020, representing
Seekingalpha · 10/09 15:09
Biofrontera concludes clinical phase of PK study with Ameluz gel in actinic keratoses
Biofrontera ([[BFRA]] -1.9%) has completed clinical phase of pharmacokinetics ((PK)) study to test the safety of photodynamic therapy ((PDT)) using three tubes of Ameluz, at the same time.Ameluz gel is
Seekingalpha · 10/08 17:01
Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study
Leverkusen, Germany, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, reports the completion of the clinical phase (last subject last visit) of the pharmacokinetics study (PK study) to test the
GlobeNewswire · 10/08 16:04
Biofrontera AG Announces German Federal Supreme Court Overturns Ruling Of Colgne Higher Regional Court Which Was Directed Against Co
Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court Leverkusen, Germany, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange:
Benzinga · 09/22 16:08
Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court
Leverkusen, Germany, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that in ruling on September 22, 2020, the German Federal Supreme Court overturned a decision by the Cologne Higher
GlobeNewswire · 09/22 16:02
Mid-Afternoon Market Update: Nasdaq Drops Over 100 Points; A-Mark Precious Metals Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.26% to 27607.31 while the NASDAQ fell 1.05% to 10805.00. The S&P also fell, dropping 0.24% to 3331.34.
Benzinga · 09/11 19:07
Mid-Day Market Update: Zumiez Surges After Q2 Results; Amyris Shares Slide
Midway through trading Friday, the Dow traded up 0.66% to 27715.14 while the NASDAQ fell 0.19% to 10898.75. The S&P also rose, gaining 0.31% to 3349.60.
Benzinga · 09/11 16:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BFRA. Analyze the recent business situations of Biofrontera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BFRA stock price target is 11.00 with a high estimate of 11.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 4
Institutional Holdings: 409
% Owned: 0.00%
Shares Outstanding: 22.42M
TypeInstitutionsShares
Increased
1
248
New
2
-46.71K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.02%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman - Supervisory/Director
Ulrich Granzer
Chairman - Management/Chief Executive Officer
Hermann Luebbert
Vice Chairman - Supervisory/Director
Juergen Baumann
Chief Financial Officer/Management Board
Thomas Schaffer
Supervisory Board
John Borer
Supervisory Board
Reinhard Eyring
Supervisory Board
Franca Ruhwedel
Supervisory Board
Kevin Weber
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BFRA
Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Biofrontera AG (ADR) stock information, including NASDAQ:BFRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BFRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BFRA stock methods without spending real money on the virtual paper trading platform.